Jennifer Newton
As the daughter of a chemistry teacher, chemistry has always been in my blood. Teaching science for 5 weeks in Ghana when I was 16 confirmed my suspicions that I didn’t also want to be a teacher.
I studied natural sciences at the University Bath, doing a little bit of everything, mainly chemistry and pharmacology but no physics. My degree included a year-long industrial placement at the Defence Science and Technology Laboratory, part of the Ministry of Defence – although if I told you what I did there, I’d have to kill you.
I joined the Royal Society of Chemistry in September 2008, collecting over 4 years of experience in journals publishing, before moving to Chemistry World in April of 2013. Cooking and gardening dominate when I'm not at work.
BusinessRoche offloads majority of rights to lebrikizumab
Deal with Dermira could be worth well over $1 billion
BusinessCelgene pays $280m to settle off-label marketing lawsuit
Whistleblower case relating to cancer prescriptions
BusinessGenesis Energy to buy alkali business from Tronox
Tronox to spend proceeds on Cristal purchase
BusinessBristol-Myers Squibb bags immunotherapy unicorn
Deal will add to pharma giant’s cancer portfolio
ResearchAlgorithm deliberately entangles MOFs
Tool tests for plausible crystal structure combinations
BusinessAramco and Shell end refining relationship
$2.2 billion divorce deal gives Aramco control of biggest oil refinery in the US
BusinessShell shrinks stake in Canadian oil sands
$7.25bn sell-off is part of plan to divest over $30bn in assets to reduce debts
BusinessFDA approves first sickle cell drug in almost two decades
Glutamine-based drug is the first approved for children over 5
BusinessLyondellBasell to build world’s largest propylene oxide plant
Petrochemical giant gets go-ahead for most expensive project to date
- Business
Pfizer to close Cambridge pain outpost
120 jobs under threat from closure of Neusentis subsidiary R&D site
- Business
Mexico approves world’s first dengue vaccine
Sanofi’s vaccine protects children and adults against the mosquito-borne disease
- Business
AstraZeneca to buy Acerta for blood cancer drug
Deal will strengthen AstraZeneca’s immunotherapy offering
BusinessDow to settle polyurethane price-fixing case
Chemical giant cancels Supreme Court appeal of damages and agrees $835m settlement
BusinessSanofi and Merck & Co end vaccines partnership
Two-decade-long alliance will split by end of 2016
